This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Global Collagen And HA-Based Biomaterials Industry

NEW YORK, March 21, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Collagen and HA-Based Biomaterials Industry http://www.reportlinker.com/p080446/Global-Collagen-and-HA-Based-Biomaterials-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biomaterial

This report analyzes the worldwide markets for Collagen and HA-Based Biomaterials in US$ Million by the following Classification based on Application Areas: Collagen Based Biomaterials (Urinary Incontinence, Corneal Shields, Facial Aesthetic Dermal Fillers, & Wound Dressings), and Hyaluronic Acid Based Biomaterials (Viscosupplements, Viscoelastics, & Facial Aesthetic Dermal Implants). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets.

The report profiles 63 companies including many key and niche players such as ABBOTT, Alcon Laboratories, Inc., Allergan, Inc., Anika Therapeutics, Inc., Bausch & Lomb, Inc., Lifecore Biomedical, LLC, Q-Med AB, Sanofi SA, Genzyme, Seikagaku Corp., and Teijin Pharma Limited.

Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONSStudy Reliability and Reporting Limitations I-1Disclaimers I-2Data Interpretation & Reporting Level I-2Quantitative Techniques & Analytics I-3Product Definitions and Scope of Study I-3Product Definitions I-4Collagen-based Biomaterials I-4Urinary Incontinence I-4Corneal Shields I-4Facial Aesthetic Dermal Fillers I-4Wound Dressings I-4Hyaluronic Acid (HA)-based Biomaterials I-4Viscosupplements I-4Viscoelastics I-4Facial Aesthetic Dermal Fillers I-5

II. EXECUTIVE SUMMARY

1. GLOBAL MARKET OVERVIEW II-1Outlook II-1Review of Major Segments II-1Collagen-Based Biomaterials II-1Urinary Incontinence II-1Corneal Shields II-2Facial Aesthetic Dermal fillers II-2Wound Dressings II-2Hyaluronic Acid-based Biomaterials II-2Viscosupplementation II-3Viscoelastics market II-3Facial Aesthetic Dermal Fillers II-3Select HA-Based Products in the Global Market II-3Regional Perspective II-4Growth Drivers- At a Glance II-4The Impact of Euro Zone Crisis on HA-Based Biomaterials Market II-4Increasing Difficulties on the Reimbursement Front II-4Increased Focus on Private Healthcare System II-5Challenges II-5Biomaterials Face Competition II-5Competitive Scenario II-5Leading Players in the Worldwide Collagen and HA-BasedBiomaterials Market II-6Table 1: Global Viscosupplements market (2011): PercentageBreakdown of Sales for Genzyme and Others (includescorresponding Graph/Chart) II-7World Collagen-based Wound Care Products (Global 2012)-Select Products and Manufacturers II-7Table 2: Global Advanced Wound Care Dressings Market (2012):Percentage Share Breakdown of Value Sales for Smith & Nephew,Convatec, Molnlycke, Coloplast, Systagenix, and Others(includes corresponding Graph/Chart) II-7

1 of 12

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,079.57 -42.44 -0.25%
S&P 500 1,996.74 -3.38 -0.17%
NASDAQ 4,557.6950 -11.9260 -0.26%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs